Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Caterpillar Inc (CAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Caterpillar Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Caterpillar Inc trades at $862.07 (market cap $387.68B). The key difference: Caterpillar Inc is far larger — about 13.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Caterpillar Inc pays a 0.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CAT | |
|---|---|---|
Market Cap | $29.60B | $387.68B |
Sector | Health | Industrials |
52-Week High | $491.22 | $1.06K |
52-Week Low | $205.48 | $407.79 |
Enterprise Value | $27.56B | $426.11B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Caterpillar (CAT) trades at $837.58, down 0.55% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q2 2026 EPS of $8.17 surpassing the $6.22 expectation. Revenue growth is supported by AI data center demand, contributing to a robust $67.59B in 2025 revenue. The stock is near key support at $831, with resistance at $850.
Outlook remains positive due to strong earnings momentum and AI-driven infrastructure demand, though elevated valuation ratios (P/E of 36.32) pose a risk. Analyst consensus is bullish with a $1,010 price target, but investors should monitor macroeconomic pressures and competitive threats. The dividend history and cash flow stability add defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Caterpillar Inc
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →
